Title |
CD80+ and CD86+B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis
|
---|---|
Published in |
Journal of Neuroinflammation, January 2014
|
DOI | 10.1186/1742-2094-11-18 |
Pubmed ID | |
Authors |
Soraya Maria Menezes, Daniele Decanine, David Brassat, Ricardo Khouri, Saul V Schnitman, Ramon Kruschewsky, Giovanni López, Carolina Alvarez, Michael Talledo, Eduardo Gotuzzo, Anne-Mieke Vandamme, Bernardo Galvão-Castro, Roland Liblau, Johan Van Weyenbergh |
Abstract |
Human T-cell lymphotropic virus (HTLV-1) is the causative agent of the incapacitating, neuroinflammatory disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Currently, there are no disease-modifying therapies with long-term clinical benefits or validated biomarkers for clinical follow-up in HAM/TSP. Although CD80 and CD86 costimulatory molecules play prominent roles in immune regulation and reflect disease status in multiple sclerosis (MS), data in HAM/TSP are lacking. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 20% |
United States | 1 | 20% |
Unknown | 3 | 60% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 80% |
Scientists | 1 | 20% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Brazil | 1 | 2% |
Unknown | 58 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 11 | 19% |
Student > Ph. D. Student | 10 | 17% |
Student > Bachelor | 7 | 12% |
Student > Master | 7 | 12% |
Student > Doctoral Student | 6 | 10% |
Other | 12 | 20% |
Unknown | 6 | 10% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 22 | 37% |
Immunology and Microbiology | 10 | 17% |
Agricultural and Biological Sciences | 9 | 15% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
Engineering | 2 | 3% |
Other | 6 | 10% |
Unknown | 8 | 14% |